Avidity launches Phase I/II muscular dystrophy treatment trial
The safety and tolerability of AOC 1020 in FSHD patients is the primary objective of the trial.
Cytiva-Cell & Gene Therapy WP 2
Latest in
Cytiva-Cell & Gene Therapy WP 2
Atamyo doses first subject in Phase I/II muscular dystrophy therapy trial
ATA-100 is a single-dose, adeno-associated virus vector with the human FKRP transgene.
Citius enters partnership for Phase I/Ib solid tumour treatment trial
The trial will evaluate the variation in the immune microenvironment within tumours, as well as in the peripheral blood.
Just announced: Covid-19 continues to dominate the infectious disease clinical trial landscape
We review recently announced late-stage clinical development plans in the infectious disease arena.
By
FDA grants IND clearance for Verismo’s cancer therapy trial
SynKIR-110 is the first product of the company to utilise the KIR-CAR platform.
Intellia, Regeneron report positive Phase I data for ATTR amyloidosis therapy
NTLA-2001 was found to be well tolerated at both dosages tested in the trial.
UK MHRA approves Avrobio’s Phase I/II Hunter syndrome therapy trial
The first trial subject is anticipated to be dosed in the first half of next year.
Nanoscope concludes enrolment in Stargardt disease gene therapy trial
The company anticipates six-month findings from the Phase II STARLIGHT trial in the first half of next year.